Abbasi O, Hirschmann J, Schmitz G, Schnitzler A, Butz M. Rejecting deep brain stimulation artefacts from MEG data using ICA and mutual information. Journal of Neuroscience Methods 2016; 268: 131-141.

Adamski N, Adler M, Opwis K, Penner IK. A pilot study on the benefit of cognitive rehabilitation in Parkinson’s disease. Therapeutic Advances in Neurological Disorders 2016; 9: 153-164.

Akkermann R, Jadasz JJ, Azim K, Küry P. Taking Advantage of Nature's Gift: Can Endogenous Neural Stem Cells Improve Myelin Regeneration? International Journal of Molecular Sciences 2016; 17; 1895.

Aktas O, Albrecht P, Hartung HP. Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and prespectives. Current Opinion in Neurology 2016; 29: 199-204.

Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. Neurology 2016; 87: 1464-1472.

Ayzenberg I, Schöllhammer J, Hoepner R, Hellwig K, Ringelstein M, Aktas O, Kümpfel T, Krumbholz M, Trebst C, Paul F, Pache F, Obermann M, Zeltner L, Schwab M, Berthele A, Jarius S, Kleiter I; Neuromyelitis Optica Study Group. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. Journal of Neurology 2016 ; 263: 575-582.

Babushok DV, Grignon AL, Li Y, Atienza J, Xie HM, Lam HS, Hartung H, Bessler M, Olson TS. Disrupted lymphocyte homeostasis in hepatitis-associated acquired aplastic anemia is associated with short telomeres. American Journal of Hematology 2016; 91: 243-247.

Bachelet D, Hässler S, Mbogning C, Link J, Ryner M, Ramanujam R, Auer M, Hyldgaard Jensen PE, Koch-Henriksen N, Warnke C, Ingenhoven K, Buck D, Grummel V, Lawton A, Donnellan N, Hincelin-Mery A, Sikkema D, Pallardy M, Kieseier B, Hemmer B, Hartung HP, Soelberg Sorensen P, Deisenhammer F, Dönnes P, Davidson J, Fogdell-Hahn A, Broët P; ABIRISK Consortium. Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. PLoS One 2016; 11: e0162752.

Balk LJ, Cruz-Herranz A, Albrecht P, Arnow S, Gelfand JM, Tewarie P, Killestein J, Uitdehaag BM, Petzold A, Green AJ. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. Journal of Neurology 2016; 263: 1323-1331.

Baumgarten TJ, Oeltzschner G, Hoogenboom N, Wittsack HJ, Schnitzler A, Lange J. Beta Peak Frequencies at Rest Correlate with Endogenous GABA+/Cr Concentrations in Sensorimotor Cortex Areas. PLoS One 2016; 11:e0156829.

Baumgarten TJ, Schnitzler A, Lange J. Prestimulus Alpha Power Influences Tactile Temporal Perceptual Discrimination and Confidence in Decisions. Cerebral Cortex 2016; 26: 891-903.

Bellebaum C, Kobza S, Ferrea S, Schnitzler A, Pollok B, Sudmeyer M. Strategies in probabilistic feedback learning in Parkinson patients OFF medication. Neuroscience 2016; 320: 8-18.

Bräutigam L, Pudelko L, Jemth AS, Gad H, Narwal M, Gustafsson R, Karsten S, Carreras Puigvert J, Homan E, Berndt C, Berglund UW, Stenmark P, Helleday T. Hypoxic Signaling and the Cellular Redox Tumor Environment Determine Sensitivity to MTH1 Inhibition. Cancer Research 2016; 76: 2366-2375.

Buerth C, Mausberg AK, Heininger MK, Hartung HP, Kieseier BC, Ernst JF. Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide. PLoS One 2016; 9; 11: e0155082.

Cameron JR, Albrecht P, Cruz-Herranz A, Petzold A, Lagreze WA, Brandt AU. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology 2016; 87: 1960.

Cao L, Klepp A, Schnitzler A, Gross J, Biermann-Ruben K. Auditory perception modulated by word reading. Experimental Brain Research 2016; 234: 3049-3057.

Carey LM, Abbott DF, Lamp G, Puce A, Seitz RJ, Donnan GA. Same Intervention-Different Reorganization: The Impact of Lesion Location on Training-Facilitated Somatosensory Recovery After Stroke. Neurorehabilitation and Neural Repair 2016; 30: 988-1000.

Cohen JA, Khatri B, Barkhof C, Comi G, Hartung HP, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L; TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery & Psychiatry 2016; 87: 468-475.

Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Multiple Sclerosis Journal 2016; 22: 862-872.

Cree BA, Hartung HP. Steering through complexity: management approaches in multiple sclerosis. Current Opinion in Neurology 2016; 29: 263-271.

Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, Schuman JS, Villoslada P, Calabresi P, Balcer L, Petzold A, Green AJ, Paul F, Brandt AU, Albrecht P; IMSVISUAL consortium. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology 2016; 86: 2303-2309.

Curtin F, Porchet H, Glanzman R, Schneble HM, Vidal V, Audoli-Inthavong ML, Lambert E, Hartung HP. A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design. Multiple Sclerosis & Related Disorders 2016; 9: 95-100.

Cutter GR, Knappertz V, Sasson N, Ladkani D. Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree. BMC Neurology 2016; 16: 176.

Dannenberg L, Erschoff V, Bönner F, Gliem M, Jander S, Levkau B, Kelm M, Hohlfeld T, Zeus T, Polzin A. Dipyrone comedication in aspirin treated stroke patients impairs outcome. Vascular Pharmacology 2016; 87: 66-69.

Diekmann H, Fischer D. Parthenolide: a novel pharmacological approach to promote nerve regeneration. Neural Regeneration Research 2016; 11: 1566-1567.

Diem R, Molnar F, Beisse F, Gross N, Drüschler K, Heinrich SP, Joachimsen L, Rauer S, Pielen A, Sühs KW, Linker RA, Huchzermeyer C, Albrecht P, Hassenstein A, Aktas O, Guthoff T, Tonagel F, Kernstock C, Hartmann K, Kümpfel T, Hein K, van Oterendorp C, Grotejohann B, Ihorst G, Maurer J, Müller M, Volkmann M, Wildemann B, Platten M, Wick W, Heesen C, Schiefer U, Wolf S, Lagrèze WA. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial study protocol. BMJ Open 2016; 6: e010956.

Dietrich M, Cruz-Herranz A, Yiu H, Aktas O, Brandt AU, Hartung HP, Green A, Albrecht P. Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide. BMJ Open Ophthalmology 2016; 1: e000008

Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T, Evdoshenko E, Thouvenot E, Trojano M, Norgren N, Teunissen C, Kappos L, Giovannoni G, Kuhle J; International Clinically Isolated Syndrome Study Group. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery & Psychiatry 2016; 87: 126-129.

Färber L, Lattrell B, Adloff AK, Welsh T, Heeschen V, Hartung HP. Hermann Oppenheim. Anmerkungen zu seinem Leben und Wirken. Nervenarzt 2016; 87: 1100-1106.

Feld M, Garcia R, Buddenkotte J, Katayama S, Lewis K, Muirhead G, Hevezi P, Plesser K, Schrumpf H, Krjutskov K, Sergeeva O, Müller HW, Tsoka S, Kere J, Dillon SR, Steinhoff M, Homey B. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. Journal of Allergy and Clinical Immunology 2016; 138: 500-508.

Fitzgerald KC, Munger KL, Köchert K, Arnason BGW, Comi G, Cook S, Goodin DS, Filippi M, Hartung H.-P., Jeffery DR, O’Connor P, Suarez G, Sandbrink R, Kappos L, Pohl C, Ascherio A. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurology 2016; 72: 1458-1465.

Florin E, Pfeifer J, Visser-Vandewalle V, Schnitzler A, Timmermann L. Parkinson subtype-specific Granger-causal coupling and coherence frequency in the subthalamic area. Neuroscience 2016; 332: 170-180-

Gascón S, Murenu E, Masserdotti G, Ortega F, Russo GL, Petrik D, Deshpande A, Heinrich C, Karow M, Robertson SP, Schroeder T, Beckers J, Irmler M, Berndt C, Angeli JP, Conrad M, Berninger B, Götz M. Identification and Successful Negotiation of a Metabolic Checkpoint in Direct Neuronal Reprogramming. Cell Stem Cell 2016; 18: 396-409.

Geiss R, Sergeyev A, Hartung H, Solntsev AS, Sukhorukov AA, Grange R, Schrempel F, Kley EB, Tünnermann A, Pertsch T. Fabrication of free-standing lithium niobate nanowaveguides down to 50 nm in width. Nanotechnology 2016; 27: 065301.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology 2016; 87; 1985-1992.

Gliem M, Schwaninger M, Jander S. Protective features of peripheral monocytes/macrophages in stroke. Biochimica et Biophysica Acta 2016; 1862: 329-338.

Gobrecht P, Andreadaki A, Diekmann H, Heskamp A, Leibinger M, Fischer D. Promotion of Functional Nerve Regeneration by Inhibition of Microtubule Detyrosination Journal of Neuroscience 2016; 36: 3890-3902.

Hahn K, Maschke M, Eggers C, Husstedt IW, Arendt G. Update HIV und Neurologie. Deutsche Medizinische Wochenschrift 2016; 141; 51-57.

Hammesfahr S, Antke C, Mamlins E, Beu M, Wojtecki L, Ferrea S, Dinkelbach L, Moldovan AS, Schnitzler A, Muller HW, Sudmeyer M. FP-CIT- and IBZM-SPECT in Corticobasal Syndrome: Results from a Clinical Follow-Up Study. Neurodegenerative Diseases 2016; 16: 342-347.

Hartmann CJ, Groiss SJ, Vesper J, Schnitzler A, Wojtecki L. Brain stimulation in Huntington's disease. Neurodegenerative Disease Management 2016; 6: 223-236.

Havla J, Warnke C, Derfuss T, Kappos L, Hartung HP, Hohlfeld R. Interdisziplinäres Risikomanagement in der Therapie der multiplen Sklerose. Deutsches Ärzteblatt 2016; 113: 879-886.

Hefter H. Inzidenz und Prävalenz neutralisierender AK in der Langzeit-Behandlung zervikaler Dystonien mit Botulinumtoxin. Thieme-Verlag, Stuttgart. 2016.

Hefter H, Rosenthal D, Moll M. High Botulinum Toxin-neutralizing antibody prevalence under long-term cervical dystonia treatment. Movement Disorders Clinical Practice 2016; 3.

Hirschmann J, Butz M, Hartmann CJ, Hoogenboom N, Ozkurt TE, Vesper J, Wojtecki L, Schnitzler. Parkinsonian Rest Tremor Is Associated With Modulations of Subthalamic High-Frequency Oscillations. Movement Disorders 2016; 31: 1551-1559.

Huppertz HJ, Moller L, Sudmeyer M, Hilker R, Hattingen E, Egger K, Amtage F, Respondek G, Stamelou M, Schnitzler A, Pinkhardt EH, Oertel WH, Knake S, Kassubek J, Hoglinger GU. Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. Movement Disorders 2016; 31: 1506-1517.

Ingwersen J, Aktas O, Hartung HP. Advances in and algorithms for the treatment of relapsing-remitting multiple sclerosis. Neurotherapeutics 2016; 13: 47-57.

Ingwersen J, Wingerath B, Graf J, Lepka K, Hofrichter M, Schröter F, Wedekind F, Bauer A, Schrader J, Hartung HP, Prozorovski T, Aktas O. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. Journal of Neuroinflammation 2016; 13: 48.

Jadasz JJ, Lubetzki C, Zalc B, Stankoff B, Hartung HP, Küry P. Recent achievements in stem cell-mediated myelin repair. Current Opinion in Neurology 2016; 29: 205-212.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Trebst C, Ringelstein M, Aktas O, Winkelmann A, Buttmann M, Schwarz A, Zimmermann H, Brandt AU, Franciotta D, Capobianco M, Kuchling J, Haas J, Korporal-Kuhnke M, Lillevang ST, Fechner K, Schanda K, Paul F, Wildemann B, Reindl M; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Journal of Neuroinflammation 2016; 13: 279.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation 2016; 13: 280.

Jarius S, Ringelstein M, Haas J, Serysheva II, Komorowski L, Fechner K, Wandinger KP, Albrecht P, Hefter H, Moser A, Neuen-Jacob E, Hartung HP, Wildemann B, Aktas O. Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. Journal of Neuroinflammation 2016; 13: 278.

Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hümmert MW, Trebst C, Pache F, Winkelmann A, Beume LA, Ringelstein M, Stich O, Aktas O, Korporal-Kuhnke M, Schwarz A, Lukas C, Haas J, Fechner K, Buttmann M, Bellmann-Strobl J, Zimmermann H, Brandt AU, Franciotta D, Schanda K, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. Journal of Neuroinflammation 2016; 13: 281.

Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. JAMA Neurology 2016; 73: 1089-1998.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 2016; 87: 978-987.

Kappos L, Arnold D, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology 2016; 15: 1148-1159.

Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR, [Jander S]; IRIS Trial Investigators.New England Journal of Medicine 2016; 374: 1321-1331.

Kieseier BC, Leussink VI, Warnke C. Natalizumab. In: Arnon, Miller (eds) Translational neuroimmunology of multiple sclerosis: from disease mechanisms to clinical applications. Elsevier, 2016, 261-276.

Kleffner I, Dörr J, Ringelstein M, Groß C, Böckenfeld Y, Schwindt W, Sundermann B, Lohmann H, Wersching H, Promesberger J, von Königsmarck N, Alex A, Guthoff R, Frijns C, Kappelle LJ, Jarius S, Wildemann B, Aktas O, Paul F, Wiendl H, Duning T; for the European Susac Consortium (EuSaC). Diagnostic criteria for Susac syndrome. Journal of Neurology, Neurosurgery & Psychiatry 2016; 87: 1287-1295.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; Neuromyelitis Optica Study Group. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Annals of Neurology 2016; 79: 206-216.

Kloeters S, Hartmann CJ, Pundmann VD, Schnitzler A, Südmeyer M, Lange J. Impaired perception of human movements in Parkinson's disease. Behavioural Brain Research 2017; 317: 88-94.

Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H. Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie. Substanzspezifische Relevanz und aktuelle Handlungsempfehlungen. Nervenarzt 2016; 87: 645-659.

Kremer D, Göttle P, Hartung HP, Küry P. Pushing forward: Remyelination as the new frontier in CNS disease. Trends in Neurosciences 2016; 39: 246-263.

Kremer D, Cui QL, Göttle P, Kuhlmann T, Hartung HP, Antel J, Küry P. CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation. PLoS One 2016;11: e0146503.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis. Multiple Sclerosis Journal 2016; 22: 533-543.

Laible M, Jarius S, Mackensen F, Schmidt-Bacher A, Platten M, Haas J, Albrecht P, Wildemann B. Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis. PLoS One 2016; 11: e0155322.

Leibinger M, Andreadaki A, Gobrecht P, Levin E, Diekmann H, Fischer D. Boosting Central Nervous System Axon Regeneration by Circumventing Limitations of Natural Cytokine Signaling. Molecular Therapy 2016; 24: 1712-1725.

Lepka K, Berndt C, Hartung HP, Aktas O. Redox events as modulators of pathology and therapy of neuroinflammatory diseases. Frontiers in Cell & Developmental Biology 2016; 4:63.

Leussink VI, Stettner M, Warnke C, Hartung HP. Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system. Journal of the Peripheral Nervous System 2016; 21: 85-87.

Leussink VI, Hartung HP, Stüve O, Kieseier BC. Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of 'Chinese restaurant syndrome'. Journal of Neurology 2016; 263 :1027-1028.

Leussink VI, Hartung HP, Kieseier BC, Stettner M. Subcutaneous immunoglobulins in the tretament of chronic-mediated neuropathies. Therapeutic Advances in Neurological Disorders 2016; 9: 336-343.

Levin E, Diekmann H, Fischer D. Highly efficient transduction of primary adult CNS and PNS neurons. Scientific Reports 2016; 6: 38928.

Lill CM, Luessi F, Alcina A, Sokolova EA, Ugidos N, de la Hera B, Guillot-Noel L, Malhotra S, Reinthaler E, Schjeide BMM, Mescheriakova JY, Maschychev A, Wohlers I, Akkad DA, Aktas O, Alloza I, Antiguedad A, Arroyo R, Astobiza I, Blaschke P, Boyko AN, Buttmann M, Chan A, Dörner T, Epplen JT, Favorova O, Fedetz M, Fernández O, Garcia-Martinez A, Gerdes, LA, Graetz C, Hartung HP, Hoffjan S, Izquierdo G, Korobko DS, Kroner A, Kubisch C, Kümpfel T, Leyva L, Lohse P, Malkova NA, Montalban X, Popova EV, Rieckmann P, Rozhdestvenskii AS, Schmied C, Smagina IV, Tsareva EY, Winkelmann A, Zettl UK, Binder H, Cournu-Rebeix I, Hintzen R, Zimprich A, Comabella M, Fontaine B, Urcelay E, Vandenbroeck K, Filipenko M, Matesanz F, Zipp F, Bertram L. Genome-wide significant association with seven novel multiple sclerosis risk loci. Journal of Medical Genetics 2016; 52: 848-855.

Lisak D, Schacht T, Gawlitza A, Albrecht P, Aktas O, Koop B, Gliem M, Hofstetter HH, Zanger K, Bultynck G, Parys JB, De Smedt H, Kindler T, Adams-Quack P, Hahn M, Waisman A, Reed JC, Hövelmeyer N, Methner A. BAX inhibitor-1 is a Ca2+ channel critically important for immune cell function and survival. Cell Death & Differentiation 2016; 23: 358-368.

Lublin F, Miller DH, Freedman MS, Cree BA., Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, et al. Oral fingolimod versus placebo in primary progressive multiple sclerosis: results of INFORMS, a large phase III, randomized, double-blind, placebo-controlled trial. Lancet 2016; 387: 1075-1084.

Mäurer M, Ortler S, Baier M, Meergans M, Scherer P, Hofmann WE, Tracik F. Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Multiple Sclerosis Journal 2016; 19: 631-638.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurology 2016; 15:574-584.

Mathys C, Caspers J, Langner R, Sudmeyer M, Grefkes C, Reetz K, Moldovan AS, Michely J, Heller J, Eickhoff CR, Turowski B, Schnitzler A, Hoffstaedter F, Eickhoff SB. Functional Connectivity Differences of the Subthalamic Nucleus Related to Parkinson's Disease. Human Brain Mapping 2016; 37: 1235-1253.

Menge T, Dubey D, Warnke C, Hartung HP, Stüve O. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics 2016; 16: 1131-1139.

Merkies IS, Kieseier BC. Fatigue, pain, anxiety and depression in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. European Neurology 2016; 75: 199-206.

Metz I, Beißbarth T, Ellenberger D, Pache F, Stork L, Ringelstein M, Aktas O, Jarius S, Wildemann B, Dihazi H, Friede T, Brück W, Ruprecht K, Paul F. Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurology, Neuroimmunology & Neuroinflammation 2016; 3: e204.

Meyer zu Hörste G, Cordes S, Pfaff J, Mathys C, Mausberg AK, Bendszus M, Pham M, Hartung HP, Kieseier BC. Predicitng the response of intravenous immunoglobulins in an animal model of chronic neuritis. PLoS One 2016; 11: e0164099.

Miclea A, Leussink VI, Hartung HP, Gold R, Hoepner R. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. Journal of Neurology 2016; 263: 1626-1632.

Newsome SD, Kieseier BC, Arnold DL, Shang S, Liu S, Hung S, Sabatella G. Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta 1a in patients with relapsing-remitting multiple sclerosis. Journal of Neurology 2016; 263: 1778-1787.

Niccolai V, van Dijk H, Franzkowiak S, Finis J, Südmeyer M, Jonas M, Thomalla G, Siebner HR, Müller-Vahl K, Münchau A, Schnitzler A, Biermann-Ruben K. Increased beta rhythm as an indicator of inhibitory mechanisms in Tourette syndrome. Movement Disorders 2016; 31: 384-392.

Niccolai V, Klepp A, Weissler H, Hoogenboom N, Schnitzler A, Biermann-Ruben K. Correction: Grasping Hand Verbs: Oscillatory Beta and Alpha Correlates of Action-Word Processing. PLoS One 2016; 11: e0161985.

Oeltzschner G, Butz M, Wickrath F, Wittsack HJ, Schnitzler A (2016) Covert hepatic encephalopathy: elevated total glutathione and absence of brain water content changes. Metabolic Brain Disease 2016; 31: 517-527.

Oeltzschner G, Schnitzler A, Wickrath F, Zollner HJ, Wittsack HJ (2016) Use of quantitative brain water imaging as concentration reference for J-edited MR spectroscopy of GABA. Magnetic Resonance Imaging 2016; 34: 1057-1063.

Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Multiple Sclerosis Journal 2016; 22: 1386-1396.

Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, Waldman A, Soelberg K, Asgari N, Ringelstein M, Aktas O, Gross N, Buttmann M, Ach T, Ruprecht K, Paul F, Brandt AU; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. Journal of Neuroinflammation 2016;13: 282.

Patejdl R, Penner IK, Noack TK, Zettl UK. Multiple sclerosis and fatigue: A revierw on the contribution of inflammation and immune-mediated neurodegeneration. Autoimmunity Reviews 2016; 15: 210-220.

Penner IK. Evaluation of cognition and fatigue in multiple sclerosis: daily practice and future directions. Acta Neurologica Scandinavica 2016; 134 Suppl. 200: 19-23.

Poulos C, Kinter E, Yang JC, Bridges JF, Posner J, Gleißner E, Mühlbacher A, Kieseier BC. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. Therapeutic Advances in Neurological Disorders 2016; 9: 95-104.

Rath J, Wurnig M, Fischmeister F, Klinger N, Höllinger I, Geißler A, Aichhorn M, Foki T, Kronbichler M, Nickel J, Siedentopf C, Staffen W, Verius M, Golaszewski S, Koppelstaetter F, Auff E, Felber S, Seitz RJ, Beisteiner R. Between- and within-site variability of fMRI localizations. Human Brain Mapping 2016; 37: 2151-2160.

Reich K, Hartung HP, Lebwohl M. More on PML in patients treated with dimethyl fumarate. New England Journal of Medicine 2016; 374: 294-295.

Rommer S, Dörner T, Freivogel K, Haas J, Kieseier BC, Kümpfel T, Paul F, Proft F, Schulze-Koops H, Schmidt E, Wiendl H, Ziemann U, Zettl UK; GRAID investigators. Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a national online registry (GRAID). Journal of Neuroimmune Pharmacology 2016; 11: 1-8.

Sadovnick AD, Traboulsee AL, Bernales CQ, Ross JP, Forwell AL, Yee IM, Guillot-Noel L, Fontaine B, Cournu-Rebeix I, Alcina A, Fedetz M, Izquierdo G, Matesanz F, Hilven K, Dubois B, Goris A, Astobiza I, Alloza I, Antigüedad A, Vandenbroeck K, Akkad DA, Aktas O, Blaschke P, Buttmann M, Chan A, Epplen JT, Gerdes LA, Kroner A, Kubisch C, Kümpfel T, Lohse P, Rieckmann P, Zettl UK, Zipp F, Bertram L, Lill CM, Fernandez O, Urbaneja P, Leyva L, Alvarez-Cermeño JC, Arroyo R, Garagorri AM, García-Martínez A, Villar LM, Urcelay E, Malhotra S, Montalban X, Comabella M, Berger T, Fazekas F, Reindl M, Schmied MC, Zimprich A, Vilariño-Güell C. Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. G3 (Bethesda) 2016; 6: 2073-2079.

Sato S, Delcourt C, Zhang S, Arima H, Heeley E, Zheng D, Al-Shahi Salman R, Stapf C, Tzourio C, Robinson T, Lindley RI, Chalmers J, Anderson CS, [Jander S]; INTERACT2 Investigators. Determinants and Prognostic Significance of Hematoma Sedimentation Levels in Acute Intracerebral Hemorrhage. Cerebrovascular Diseases 2016; 41: 80-86.

Schippling S, O'Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, Cook S, Filippi M, Hartung HP, Comi G, Jeffery DR, Kappos L, Goodin DS, Arnason B. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. Journal of Neurology 2016; 263: 1418-1426.

Schneider R, Koop B, Schröter F, Cline J, Ingwersen J, Berndt C, Hartung HP, Aktas O, Prozorovski T. Activation of Wnt signaling promotes hippocampal neurogenesis in experimental autoimmune encephalomyelitis. Molecular Neurodegeneration 2016; 11: 53.

Seinstra M, Wojtecki L, Storzer L, Schnitzler A, Kalenscher T. No Effect of Subthalamic Deep Brain Stimulation on Intertemporal Decision-Making in Parkinson Patients. eNeuro 2016; 3: 1-12.

Seitz RJ. The pros and cons of intravenous thrombolysis in stroke. Lancet Neurology 2016; 15: 997-998.

Seitz RJ, Paloutzian RF, Angel HF. Processes of believing: Where do they come from? What are they good for? F1000Research 2016; 5; 2573.

Stankoff B, Jadasz JJ, Hartung HP, Küry P, Zalc B, Lubetzki C. Repair strategies for multiple sclerosis: challenges, achievements and perspectives. Current Opinion in Neurology 2016; 29: 286-292.

Steckner C, Weber A, Mausberg AK, Heininger M, Opdenhövel F, Kieseier BC, Hartung HP, Hofstetter HH. Alteration of the cytokine signature by various TLR ligands in different T cell populations in MOG37-50 and MOG35-55-induced EAE in C57BL/6 mice. Clinical Immunology 2016; 170: 22-30.

Storzer L, Butz M, Hirschmann J, Abbasi O, Gratkowski M, Saupe D, Schnitzler A, Dalal SS. Bicycling and Walking are Associated with Different Cortical Oscillatory Dynamics. Frontiers in Human Neuroscience 2016; 10: 61.

Szepanowski F, Derksen A, Steiner I, Meyer Zu Hörste G, Daldrup T, Hartung HP, Kieseier BC. Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling. Journal of Neuroinflammation 2016; 13: 143.

Trenado C, Hartmann CJ, Elben S, Pauls KA, Friggemann L, Groiss SJ, Timmermann L, Vesper J, Schnitzler A, Wojtecki L. Local field potential oscillations of the globus pallidus in cervical and tardive dystonia. Journal of Neurological Sciences 2016; 366: 68-73.

van Schaik IN, van Geloven N, Bril V, Hartung HP, Lewis RA, Sobue G, Lawo JP, Mielke O, Cornblath DR, Merkies IS; PATH study group. Subcutaneus immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. Trials 2016; 17: 345.

Warnke C, Wattjes MP, Adams O, Hartung HP, Martin R, Weber T, Stangel M. Progressive multifokale Leukencephalopathie. Nervenarzt 2016 ; 87: 1300-1304.

Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry 2016; 87: 1005-1015.

Wattjes MP, Warnke C. Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good? Journal of Neurology, Neurosurgery & Psychiatry 2016; 87: 115.

Weber A, Zimmermann C, Mausberg AK, Dehmel T, Kieseier BC, Hartung HP, Hofstetter HH. Pseudomonas aeruginosa and Its Bacterial Components Influence the Cytokine Response in Thymocytes and Splenocytes. Infection and Immunity 2016; 84: 1413-1423.

Weil MT, Möbius W, Winkler A, Ruhwedel T, Wrzos C, Romanelli E, Bennett JL, Enz L, Goebels N, Nave KA, Kerschensteiner M, Schaeren-Wiemers N, Stadelmann C, Simons M. Loss of myelin basic protein function triggers myelin breakdown in models of demyelinating diseases. Cell Reports 2016; 16: 314-322.

White JT, Newsome SD, Kieseier BC, Bermel RA, Cui Y, Seddighzadeh A, Hung S, Crossman M, Subramanyam M. Incidence, characterization and clinical impact analysis of peginterferon beta 1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. Therapeutic Advances in Neurological Disorders 2016; 9: 239-249.

Winkelmann A, Lobermann M, Reisinger EC, Hartung HP, Zettl UK. Disease modifying therapies and infectious risks in multiple sclerosis. Nature Reviews Neurology 2016; 12: 217-233

Winter M, Baksmeier C, Steckel J, Barman S, Malviya M, Harrer-Kuster M, Hartung HP, Goebels N. Dose-dependent inhibition of demyelination and microglia activation by IVIG. Annals of Clinical & Translational Neurology 2016; 3: 828-843.

Wojtecki L, Elben S, Rübenach J, Hartmann C, Vesper J, Schnitzler A. Subthalamic Deep Brain Stimulation in Obsessive-Compulsive Disorder: First German Experience and Future Outlook. World Neurosurgery 2016; 95: 607-608.

Wojtecki L, Groiss SJ, Hartmann CJ, Elben S, Omlor S, Schnitzler A, Vesper J. Deep Brain Stimulation in Huntington's Disease-Preliminary Evidence on Pathophysiology, Efficacy and Safety. Brain Science 2016; 6: 38.

Zeus T, Ketterer U, Leuf D, Dannenberg L, Wagstaff R, Bönner F, Gliem M, Jander S, Kelm M, Polzin A. Troponin T in Prediction of Culprit Lesion Coronary Artery Disease and 1-Year Major Adverse Cerebral and Cardiovascular Events in Patients with Acute Stroke. Translational Stroke Research 2016; 7:180-185.

Zeus T, Ketterer U, Leuf D, Dannenberg L, Bönner F, Wagstaff R, Gliem M, Jander S, Kelm M, Polzin A. Safety of percutaneous coronary intervention in patients with acute ischemic stroke/transient ischemic attack and acute coronary syndrome. Clinical Research in Cardiology 2016; 105: 356-363.

Zheng D, Arima H, Sato S, Gasparrini A, Heeley E, Delcourt C, Lo S, Huang Y, Wang J, Stapf C, Robinson T, Lavados P, Chalmers J, Anderson CS, [Jander S]; INTERACT2 investigators. Low Ambient Temperature and Intracerebral Hemorrhage: The INTERACT2 Study. PLoS One 2016; 11: e0149040.

Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. BMC Neurology 2016; 16: 98.

MediathekInformation und Wissen
LageplanSo finden Sie uns